Adaptive Biotechnologies Corp (NASDAQ: ADPT) Executive Sells Shares

Font: Financial Modeling Prep  • Apr 17, 2026

• Adaptive Biotechnologies Corp (NASDAQ: ADPT), a biotechnology company, maintains a market capitalization of approximately $2.17 billion, with its stock currently trading at $14.08.
• President and COO Julie Rubinstein conducted multiple executive stock sales throughout April, totaling 95,300 shares, with transaction prices ranging from $12.77 to $14.18.
• These insider transactions were executed under a pre-arranged Rule 10b5-1 trading plan, a common practice for company insiders to avoid claims of trading on non-public information.

Adaptive Biotechnologies Corp (NASDAQ: ADPT) is a biotechnology company with a market capitalization of approximately $2.17 billion. The company's stock currently trades at $14.08, having moved between a low of $6.78 and a high of $20.76 over the past 52 weeks. Adaptive Biotechnologies Corp is listed and traded on the NASDAQ exchange, reflecting its position in the biotech stock market.

On April 16, 2026, company President and COO Julie Rubinstein sold 19,060 shares of common stock. The shares were sold at a price of $14.18 each. Following this executive stock sale, Rubinstein's direct holdings in Adaptive Biotechnologies Corp were adjusted to 408,160 shares, a detail investors often monitor as an indicator of executive confidence and insider activity.

This sale is part of a pattern of recent insider transactions by the executive. As highlighted by defenseworld.net, Rubinstein also sold 19,060 shares on April 13th at an average price of $13.15 and another 19,060 shares on April 10th at $12.77 each. These consistent stock sales provide a broader picture of her trading activity.

These executive transactions were conducted under a pre-arranged Rule 10b5-1 trading plan. Such plans are set up in advance by company insiders to automatically sell a predetermined number of shares at a specific time. This helps executives avoid any claims of trading on private, non-public information about the company's future, ensuring compliance with insider trading rules.

Earlier in the month, between April 1st and April 2nd, Rubinstein sold 38,120 shares for about $554,000.00, as reported by fool.com. This series of insider stock sales, executed under the trading plan, shows a consistent reduction in her insider holdings throughout the month, starting from a position of 447,202 shares.